Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options

被引:79
|
作者
Sterkens, A. [1 ]
Lambert, J. [1 ]
Bervoets, A. [1 ]
机构
[1] Univ Hosp Antwerp, Dept Dermatol, Wilrijkstr 10, B-2650 Edegem, Belgium
关键词
Alopecia areata; Dendritic cells; Immunology; Langerhans cells; Treatment; JANUS KINASE INHIBITOR; PLATELET-RICH PLASMA; 308-NM EXCIMER-LASER; HUMAN HAIR FOLLICLE; CLASS-I EXPRESSION; DENDRITIC CELLS; IMMUNE PRIVILEGE; TOPICAL IMMUNOTHERAPY; LANGERHANS CELLS; ANDROGENETIC ALOPECIA;
D O I
10.1007/s10238-020-00673-w
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Patients suffering from alopecia areata (AA) can lose hair in focal regions, the complete scalp, including eyelashes and eyebrows, or even the entire body. The exact pathology is not yet known, but the most described theory is a collapse of the immune privilege system, which can be found in some specific regions of the body. Different treatment options, local and systemic, are available, but none of them have been proven to be effective in the long term as well for every treatment there should be considered for the possible side effects. In many cases, treated or non-treated, relapse often occurs. The prognosis is uncertain and is negatively influenced by the subtypes alopecia totalis and alopecia universalis and characteristics such as associated nail lesions, hair loss for more than 10 years and a positive familial history. The unpredictable course of the disease also makes it a mental struggle and AA patients are more often associated with depression and anxiety compared to the healthy population. Research into immunology and genetics, more particularly in the field of dendritic cells (DC), is recommended for AA as there is evidence of the possible role of DC in the treatment of other autoimmune diseases such as multiple Sclerosis and cancer. Promising therapies for the future treatment of AA are JAK-STAT inhibitors and PRP.
引用
收藏
页码:215 / 230
页数:16
相关论文
共 50 条
  • [1] Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options
    A. Sterkens
    J. Lambert
    A. Bervoets
    Clinical and Experimental Medicine, 2021, 21 : 215 - 230
  • [2] Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management
    Cheng Zhou
    Xiangqian Li
    Chen Wang
    Jianzhong Zhang
    Clinical Reviews in Allergy & Immunology, 2021, 61 : 403 - 423
  • [3] Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management
    Zhou, Cheng
    Li, Xiangqian
    Wang, Chen
    Zhang, Jianzhong
    CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2021, 61 (03) : 403 - 423
  • [4] Diagnosis and treatment of alopecia areata
    Lee, Young
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2016, 59 (11): : 866 - 871
  • [5] Diagnosis and treatment of alopecia areata
    Berard, F
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2000, 127 : S29 - S33
  • [6] A Case of Alopecia areata Treated with DPCP Review of Current Treatment Options
    Dumke, A. -K.
    Rhein, D.
    Elsner, P.
    AKTUELLE DERMATOLOGIE, 2012, 38 (8-9) : 326 - 330
  • [7] ALOPECIA AREATA - IMMUNOLOGICAL STUDIES AND TREATMENT WITH PREDNISONE
    KERN, F
    HOFFMAN, WH
    BLIZZARD, RM
    HAMBRICK, GW
    ARCHIVES OF DERMATOLOGY, 1973, 107 (03) : 407 - 412
  • [8] Treatment Options for Alopecia Areata in Children and Adolescents
    Westerkam, Linnea L.
    McShane, Diana B.
    Nieman, Elizabeth L.
    Morrell, Dean S.
    PEDIATRIC DRUGS, 2024, 26 (03) : 245 - 257
  • [9] Alopecia Areata: An Update on Treatment Options for Children
    Peloquin, Lauren
    Castelo-Soccio, Leslie
    PEDIATRIC DRUGS, 2017, 19 (05) : 411 - 422
  • [10] Treatment Options for Alopecia Areata in Children and Adolescents
    Linnea L. Westerkam
    Diana B. McShane
    Elizabeth L. Nieman
    Dean S. Morrell
    Pediatric Drugs, 2024, 26 : 245 - 257